Comparative evaluation of efficacy of Pinaverium monotherapy and combination therapy of Pinaverium with itopride hydrochloride in patients with cross irritable bowel syndrome with constipation and postpradial distress syndrome
https://doi.org/10.33667/2078-5631-2019-2-20(395)-54-57
Abstract
Forty-seven patients with overlap between irritable bowel syndrome with constipation and (IBS-C) and postpradial distress syndrome (PDS) complying with Rome III criteria were treated with pinaverium in combination with itopride and 58 patients with IBS-C-PDS overlap were treated with pinaverium for 4 weeks. Clinical symptoms and quality of life by SF-36 were estimated at baseline and after 4 weeks of treatment. Pinaverium and Itopride combination therapy significantly improved both IBS-C and PDS-like symptoms, and SF-36 scores when compared to Pinaverium monotherapy over a 4-week period.
About the Authors
O. V. Krapivnaya
Railway Clinical Hospital
Russian Federation
Russian Federation
Khabarovsk
S. A. Alekseenko
Far East State Medical University
Russian Federation
Russian Federation
Khabarovsk
References
1. Suzuki H., Hibi T. Overlap syndrome of functional dyspepsia and irritable bowel syndrome — are both diseases mutually exclusive? // Neurogastroenterol Motil. — 2011. — Vol. 17, No. 4. — P. 360–365.
2. Ford A. C., Marwaha A., Lim A., Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia // Clin Gastroenterol Hepatol. — 2010. — Vol. 8. — P. 401–409.
3. Wang A., Liao X., Xiong L., Peng S., Xiao Y., Liu S., Hu P., Chen M. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria // BMC Gastroenterol. — 2008. — Vol. 8. — P. 43.
4. Matsuzaki J., Suzuki H., Asakura K., Fukushima Y., Inadomi J. M., Takebayashi T., Hibi T. Classification of functional dyspepsia based on concomitant bowel symptoms // Neurogastroenterol Motil. — 2012. — Vol. 24, No. 4. — P. 325–364.
5. Крапивная О. В., Алексеенко С. А. Влияние комбинированной терапии пинаверия бромидом и итопридом гидрохлоридом на клиническую симптоматику и качество жизни пациентов с сочетанием обстипационного варианта синдрома раздраженного кишечника и функциональной диспепсии // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. — 2015. — Т. 25, № 2. — С. 22–27.
6. Tack J., Talley N. J., Camilleri M., Holtmann G., Hu P., Malagelada JR., Stanghellini V. Functional gastroduodenal disorders // Gastroenterology. — 2006. — Vol. 130, No. 5. — P. 1466–1479.
7. Stanghellini V., Chan F. K., Hasler W. L., Malagelada J. R., Suzuki H., Tack J., Talley N. J. Gastroduodenal Disorders // Gastroenterology. — 2016. — Vol. 150, No. 6. — P. 1380–1392.
8. Huang X., Lv B., Zhang S., Fan Y. H., Meng L. N. Itopride therapy for functional dyspepsia: a meta-analysis // World J Gastroenterol. — 2012. — Vol. 18, No. 48. — P. 7371–7377.
9. Lacy B. E., Mearin F., Chang L. et al. Bowel Disorders // Gastroenterology. — 2016. — Vol. 150, No. 6. — P. 1393–1407.
10. Ruepert L., Quartero A. O., de Wit N. J., van der Heijden G. J., Rubin G., Muris J. W. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome // The Cochraine Library. — 2013. — Issue 3.
11. Longstreth G. F., Thompson W. G., Chey W. D., Houghton L. A., Mearin F., Spiller R. C. Functional bowel disorders // Gastroenterologyю — 2006. — Vol. 130, No. 5. — P. 1480–4191.
12. Miller, L. E. Study design considerations for irritable bowel syndrome clinical trials // Ann Gastroenterol. — 2014. — Vol. 27, No. 4. — P. 338–345.
13. Wong R. K., Palsson O. S., Turner M. J. et al. Inability of the Rome III Criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome // Am J Gastroenterol. — 2010. — Vol. 105. — P. 2228–2234.
14. Ware J. E., Sherbourne C. D. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection // Med Care. — 1992. — Vol. 30. — P. 473–483.
15. Mushiroda T., Douya R., Takahara E., Nagata O. The Involvement of Flavin-Containing Monooxygenase but Not CYP3A4 in Metabolism of Itopride Hydrochloride, a Gastroprokinetic Agent: Comparison with Cisapride and Mosapride Citrate // Drug Metab Dispos. — 2000. — Vol. 28, No. 10. — P. 1231–1237.
16. Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome // World Journal of Gastroenterology. — 2014. — Vol. 20, No. 20. — P. 6031–6043.
Review
For citations:
Krapivnaya O.V., Alekseenko S.A. Comparative evaluation of efficacy of Pinaverium monotherapy and combination therapy of Pinaverium with itopride hydrochloride in patients with cross irritable bowel syndrome with constipation and postpradial distress syndrome. Medical alphabet. 2019;3(20):54-57. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-20(395)-54-57
Views:
397
Email this article 